Sentences with phrase «of cancer immunology»

Under the new model — to which Stanford University, Memorial Sloan Kettering Cancer Center and other major institutions agreed — nearly 300 researchers specializing in the white - hot field of cancer immunology across the country will be following the lead of this central steering committee in determining the direction of their research.

«These exciting results indicate that there is a new standard of care option for a population of head and neck cancer patients with no other treatment options,» said the trial's international co-chair Robert Ferris, M.D., Ph.D., UPMC Endowed Professor, and chief of the Division of Head and Neck Surgery and co-leader of the Cancer Immunology Program at UPCI.

«This pathway is very important in balancing immunity against pathogens and tolerance against self,» says Zihai Li, M.D., Ph.D., professor and chair of Microbiology and Immunology at MUSC, co-leader of the Cancer Immunology Program at the MUSC Hollings Cancer Center, and senior author for this study.

On September 1, 2011, Hyam I. Levitsky, M.D., a member of the executive committee of the CRI Cancer Immunotherapy Consortium, was named head of cancer immunology experimental medicine at Roche, one of the world's largest pharmaceutical companies.

Department of Cancer Immunology and Virology, Intel Parallel Computing Center for Structural Biology, Dana - Farber Cancer Institute, Boston, MA 02215, USA.

Building on the advancements made in other solid tumors, as well as a better understanding of cancer immunology, provides hope for the development of novel and effective immunotherapies in the treatment of sarcoma.

«In recent years, several therapeutic medicines have been developed that spur a person's own immune system to fight cancer,» said Raul Torres, PhD, professor of immunology at National Jewish Health, and senior author on the paper, published in the October issue of Cancer Immunology Research.

Tumors are home to diverse immune cell types, some of which remain much less explored than T cells and could also control cancer progression» says Mikael Pittet, PhD, director of the Cancer Immunology Program in the MGH Center for Systems Biology and senior author of the Science paper.

CRI commences workshops exploring topics at the cutting - edge of cancer immunology.

At the dinner, Parker also received the organization's highest honor for lay individuals, the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research, for his outspoken endorsement of cancer immunotherapy and substantial financial support of the Cancer Immunology Translational Research Dream Team that is jointly funded by CRI and Stand Up To Cancer, an organization to which Parker has strong ties.

She is an active member of ASCO, AACR, and SITC, and is a member of the Cancer Immunology (CIMM) Working Group of the AACR.

She is a member of the Department of Pathology at Brigham and Women's Hospital, an Associate Member at the Broad Institute of MIT and Harvard, and Leader of the Cancer Immunology Program at the Dana - Farber / Harvard Cancer Center.

The scientific goal of the Cancer Immunology Program is to understand the basic mechanisms by which the immune system is regulated in cancer and to apply these discoveries to the development of immunotherapy trials.

It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction / integration, innovation, translation and leadership in the field.

CRI CEO and director of scientific affairs Jill O'Donnell - Tormey says she is gratified to see the field of cancer immunology finally receiving mainstream acceptance.

This 48 - page retrospective helps readers understand the central role that CRI has played in bringing the field of cancer immunology to its current era of fruition, and what it is doing to set the pace for the future.

Dr. Lieping Chen currently serves as the United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Dermatology and Medical Oncology at Yale School of Medicine and co-Director of the Cancer Immunology Program of Yale Cancer Center in New Haven, CT..

Award winners are nominated by CRI's Scientific Advisory Council, the Academy of Cancer Immunology, and former Coley Award winners.

«Pancreatic cancer cells are deadly because they program nearby immune cells to permit the tumors to survive and grow,» says study author George Miller, MD, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU Langone.

Professor of Microbiology & Immunobiology, Harvard Medical School Chair & Professor; Department of Cancer Immunology & Virology, Dana - Farber Cancer Institute

Building off of our early successes in the clinic, we have built a dedicated effort to understand how a patient's immune response can be activated to achieve durable benefit and potentially cure, extending our understanding of cancer immunology to pursue new and innovative targets.

«We have experiments in mice that show that the combined use of PD - 1 antibody and poly - IC is synergistic for the recognition of tumors and an antitumor response mediated by T - cells,» says Dr. Esteban Celis, co-leader of the Cancer Immunology, Inflammation and Tolerance program at the Georgia Cancer Center at Augusta University.

This annual award recognizes the contributions of individuals, corporations, and foundations that have made a significant impact on medical research, patient care, or public education in the fields of cancer immunology and immunotherapy.

This is an exciting time for the field of cancer immunology: basic science is having an important translational impact and immunotherapy is emerging as a major cancer therapeutic modality.

Having helped to establish the field of cancer immunology, which is now on a firm scientific footing and gaining momentum, CRI is placing an increasing emphasis on the translation and clinical application of scientific discovery and identifying innovative ways to help bring the most promising immunotherapies to more cancer patients sooner.

The 2017 Warren Alpert Foundation Prize has been awarded to five scientists for transformative discoveries in the field of cancer immunology.

Drew Pardoll, co-director of cancer immunology at the Johns Hopkins School of Medicine, said he expects the FDA to approve immune drugs for bladder cancer, kidney cancer and Hodgkin's lymphoma this year.

Gert Riethmüller, M.D., a Scientific Advisory Council member and a member of the Academy of Cancer Immunology, conducted key research that led to a patent for blinatumomab.

Allison, Chen, Freeman, Honjoand Sharpe are indisputable standouts in the field of cancer immunology,» said Bevin Kaplan, director of the Warren Alpert Foundation.